Research Portal

U.S.-listed market research with live data and structured thesis notes.

Side-by-side research view

Compare names across metrics and research quality

Use up to 4 U.S.-listed names from this dashboard to compare valuation, growth, cash flow, balance-sheet strength, and the curated investment case in one place.

1 stocks in current compare
4 max names side by side
24 shared metrics lined up

Build a compare set

Enter comma-separated tickers from the dashboard universe. Duplicate tickers are ignored automatically.

Clear
Compute Stack AI Platforms Power Buildout Robotics
ISRG Robotics

Intuitive Surgical

Surgical robotics leader

Detail page

Intuitive is the dominant public surgical robotics franchise and belongs in any serious robotics basket.

Price $477.97
1D change -0.41%
Market cap $169.76B
Sector —

Shared metric table

Live market metrics plus reported quarterly revenue and profit QoQ rows.

Green and red only apply where direction is meaningful. Quarterly revenue and profit cells inherit the sign of the reported QoQ change, which can swing sharply when the prior quarter included a one-time item.

Metric ISRG
Price $477.97
1D Change -0.41%
Market Cap $169.76B
Enterprise Value —
Trailing P/E 60.6
Forward P/E 41.8
Price / Sales —
EV / Revenue —
Revenue Growth —
Earnings Growth —
Gross Margin —
Operating Margin —
Net Margin —
ROE —
Free Cash Flow —
FCF Margin —
Debt / Equity —
Current Ratio —
Dividend Yield —
Next Earnings Apr 21, 2026
Quarterly Revenue $2.87B
Revenue QoQ +14.4%
Quarterly Net Income $794.8M
Net Income QoQ +12.8%

ISRG thesis lens

Surgical robotics leader

Why it could benefit

  • Intuitive is the dominant public surgical robotics franchise and belongs in any serious robotics basket.
  • Its installed base, procedure growth, and recurring instruments model create a stronger moat than most robotics names.
  • This adds a high-quality medical robotics angle that is less tied to data-center spending or industrial cycles.

Moat / edge

  • Large installed base and deep surgeon training ecosystem.
  • Recurring revenue from instruments, accessories, and service.
  • Years of lead time and brand strength in robotic-assisted surgery.

What to watch

  • Procedure growth and system placements.
  • Adoption of newer da Vinci platforms and adjacent products.
  • Gross-margin resilience as the business scales.

Key risks

  • Premium valuation can leave less room for execution misses.
  • Hospital capital-spending cycles still matter.